Immunai, a New York based biotech company, raised $60M in Series A funding, increasing total funding-to-date to over $80M.
The Series A round was led by Schusterman Family Investments, Duquesne Family Office, Catalio Capital Management, and Dexcel Pharma, with participation from existing investors Viola Ventures and TLV Partners.
The company will use these funds to expand AMICATM, its proprietary Annotated Multi-omic Immune Cell Atlas, and extend its functional genomics capabilities to reprogram immune cells and validate targets to better support discovery, prioritization, and development of new therapies and drug combinations.
Led by Noam Solomon, co-founder and CEO, and and Luis Voloch, co-founder and CTO, Immunai reprograms the immune system to advance personalized medicine to detect, diagnose, and treat disease. The company, which also has offices in San Francisco and Tel Aviv, has the ability to annotate and characterize single cells at high resolution to provide the potential for insights into the regulation and function of the immune system in disease and leading to the discovery and development of effective and targeted immunotherapies.
By partnering with pharmaceutical, biotech, and academic leaders and building its own pipeline, Immunai can answer the most pressing questions in immuno-oncology, cell therapy, infectious disease, and autoimmunity, including key biology driving clinical endpoints and target discovery.